Cargando…
Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR
OBJECTIVES: This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy. MATERIALS AND METHODS: We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805545/ https://www.ncbi.nlm.nih.gov/pubmed/29467959 http://dx.doi.org/10.18632/oncotarget.23612 |